Daniel F. Cardozo Pinto

Daniel F. Cardozo Pinto

Auto-generated profile, based on publicly available information

Daniel F. Cardozo Pinto

Nancy Pritzker Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BHBoris D. Heifets
Boris D. Heifets
JSJuliana S. Salgado
Juliana S. Salgado
MTMadison D. Taylor
Madison D. Taylor
PHPaul Hoerbelt
Paul Hoerbelt
DPDaniel F. Cardozo Pinto
Daniel F. Cardozo Pinto
RMRobert C. Malenka
Robert C. Malenka
The extensively abused recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA) has shown promise as an adjunct to psychotherapy for treatment-resistant psychiatric disease. It is unknown, however, whether the mechanisms underlying its prosocial therapeutic effects and abuse potential are distinct. We modeled both the prosocial and nonsocial drug reward of MDMA in mice and investigated the mechanism of these processes using brain region–specific pharmacology, transgenic manipulations, electrophysiology, and in vivo calcium imaging. We demonstrate in mice that MDMA acting at the serotonin transporter within the nucleus accumbens is necessary and sufficient for MDMA’s prosocial effect. MDMA’s acute rewarding properties, in contrast, require dopaminergic signaling. MDMA’s prosocial effect requires 5-HT1b receptor activation and is mimicked by d-fenfluramine, a selective serotonin-releasing compound. By dissociating the mechanisms of MDMA’s prosocial effects from its addictive properties, we provide evidence for a conserved neuronal pathway, which can be leveraged to develop novel therapeutics with limited abuse liability.

11 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
DPDaniel F. Cardozo Pinto
Daniel F. Cardozo Pinto
HYHongbin Yang
Hongbin Yang
IDIskra Pollak Dorocic
Iskra Pollak Dorocic
JJJohannes W. de Jong
Johannes W. de Jong
VHVivian J. Han
Vivian J. Han
SLStephan Lammel
Stephan Lammel
The dorsal raphe (DR) is a heterogeneous nucleus containing dopamine (DA), serotonin (5HT), γ-aminobutyric acid (GABA) and glutamate neurons. Consequently, investigations of DR circuitry require Cre-driver lines that restrict transgene expression to precisely defined cell populations. Here, we present a systematic evaluation of mouse lines targeting neuromodulatory cells in the DR. We find substantial differences in specificity between lines targeting DA neurons, and in penetrance between lines targeting 5HT neurons. Using these tools to map DR circuits, we show that populations of neurochemically distinct DR neurons are arranged in a stereotyped topographical pattern, send divergent projections to amygdala subnuclei, and differ in their presynaptic inputs. Importantly, targeting DR DA neurons using different mouse lines yielded both structural and functional differences in the neural circuits accessed. These results provide a refined model of DR organization and support a comparative, case-by-case evaluation of the suitability of transgenic tools for any experimental application.

25 November 2024 in Nature
Verified
Journal Article
Closed access
PDF file
DPDaniel F. Cardozo Pinto
Daniel F. Cardozo Pinto
MPMatthew B. Pomrenze
Matthew B. Pomrenze
MGMichaela Y. Guo
Michaela Y. Guo
GTGavin Touponse
Gavin Touponse
ACAllen Chen
Allen Chen
RMRobert C. Malenka
Robert C. Malenka

8 July 2021 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
JWJessica J. Walsh
Jessica J. Walsh
PLPierre Llorach
Pierre Llorach
DPDaniel F. Cardozo Pinto
Daniel F. Cardozo Pinto
WWWendy Wenderski
Wendy Wenderski
DCDaniel J. Christoffel
Daniel J. Christoffel
RMRobert C. Malenka
Robert C. Malenka

1 July 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
DPDaniel F. Cardozo Pinto
Daniel F. Cardozo Pinto
SLStephan Lammel
Stephan Lammel

24 July 2025 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
MPMatthew B. Pomrenze
Matthew B. Pomrenze
SVSam Vaillancourt
Sam Vaillancourt
JSJuliana S. Salgado
Juliana S. Salgado
KRKendall B. Raymond
Kendall B. Raymond
PLPierre Llorach
Pierre Llorach
BHBoris D. Heifets
Boris D. Heifets
MDMA is a promising adjunct to psychotherapy and has well-known abuse liability, although less than other amphetamine analogs. While the reinforcing dopamine (DA)-releasing properties of MDMA are on par with methamphetamine (METH), MDMA is a far more potent serotonin (5-HT) releaser, via the 5-HT transporter (SERT). MDMA-mediated 5-HT release in a major reward center, the nucleus accumbens (NAc), drives prosocial behaviors via 5-HT1BR activation. We hypothesized that this prosocial mechanism contributes to the reduced reinforcing properties of MDMA compared to METH and used a platform of assays to predict the balance of prosocial and abuse-linked effects of (R)-MDMA, a novel entactogen in clinical development. NAc DA release, measured by GRAB-DA photometry in vivo, increased in proportion to MDMA (7.5 and 15 mg/kg, i.p.) and METH (2 mg/kg i.p.)-conditioned place preference (CPP). Using conditional knockouts (cKOs) for DAT and SERT, microdialysis, and photometry, we found that MDMA-released 5-HT limited MDMA-released DA through actions in the NAc, rather than at ventral tegmental area DAergic cell bodies. SERT cKO reduced the MDMA dose required for CPP three-fold. This enhanced MDMA-CPP and increased DA release were replicated by intra-NAc infusion of either a 5-HT reuptake inhibitor (escitalopram) to prevent MDMA interaction with SERT, or a 5-HT2CR antagonist (SB242084), but not by the 5-HT1BR antagonist NAS-181. These data support separate mechanisms for the low abuse potential versus prosocial effect of MDMA. Using this platform of assays, (R)-MDMA is predicted to have prosocial effects and low abuse potential.